Dr. Reddy’s Gains Oncology Asset In Eisai Spring Cleaning

In an apparent push to shed assets it considers non-core before the end of its fiscal year, Eisai is transferring most of its global rights to an oncology product to Dr. Reddy's, in the process bolstering the Indian firm's novel cancer pipeline and strategic interest in the dermatology space.